Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Progesterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Progesterone SCHEMBL8430168 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL13259536 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL7671 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL15224316 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL20342397 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL3932110 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL23568915 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL12090497 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL17750737 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL20409003 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113616594-A | Preparation of progesterone nanocrystalline injection | 南京泽恒医药技术开发有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-109223722-B | Progesterone nano crystal injection and its preparing method | 广州中医药大学(广州中医药研究院) | 2021-04-30 | — | — | CN | disclosed |
| US-20160184322-A1 | USE OF ent-PROGESTERONE TO BETTER OUTCOMES ASSOCIATED WITH TBI AND mTBI | PREVACUS INC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184322-A1 | USE OF ent-PROGESTERONE TO BETTER OUTCOMES ASSOCIATED WITH TBI AND mTBI | PREVACUS INC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160168188-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160168190-A1 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | ORAGENICS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160168190-A1 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | ORAGENICS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160168188-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160108081-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS INC (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160108081-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS INC (US) | 2016-04-21 | — | — | US | disclosed |
| US-20140275572-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS INC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275572-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS INC (US) | 2014-09-18 | — | — | US | disclosed |
| US-8492368-B2 | Nasal delivery mechanism for prophylactic and post-acute use of progesterone and/or its enantiomer for use in treatment of mild traumatic brain injuries | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492368-B2 | Nasal delivery mechanism for prophylactic and post-acute use of progesterone and/or its enantiomer for use in treatment of mild traumatic brain injuries | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130090316-A1 | Nasal Delivery Mechanism for Prophylactic and Post-Acute Use of Progesterone and/or its Enantiomer for Use in Treatment of Mild Traumatic Brain Injuries | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090315-A1 | PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE TO BETTER OUTCOMES ASSOCIATED WITH CONCUSSION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090317-A1 | PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE IN CONJUNCTION WITH ITS ENANTIOMER FOR USE IN TREATMENT OF TRAUMATIC BRAIN INJURIES | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090316-A1 | Nasal Delivery Mechanism for Prophylactic and Post-Acute Use of Progesterone and/or its Enantiomer for Use in Treatment of Mild Traumatic Brain Injuries | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090317-A1 | PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE IN CONJUNCTION WITH ITS ENANTIOMER FOR USE IN TREATMENT OF TRAUMATIC BRAIN INJURIES | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090315-A1 | PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE TO BETTER OUTCOMES ASSOCIATED WITH CONCUSSION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090316-A1 | Nasal Delivery Mechanism for Prophylactic and Post-Acute Use of Progesterone and/or its Enantiomer for Use in Treatment of Mild Traumatic Brain Injuries | CRH, PGR, PGRMC2 | PGR 2/4885CYP3A4 1889/4885LMNA 746/4885 |
| US-20130090315-A1 | PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE TO BETTER OUTCOMES ASSOCIATED WITH CONCUSSION | SHBG, PGR, SERPINA6 | PGR 2/4885CYP3A4 1505/4885LMNA 517/4885 |
| US-20130090317-A1 | PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE IN CONJUNCTION WITH ITS ENANTIOMER FOR USE IN TREATMENT OF TRAUMATIC BRAIN INJURIES | PGR, SHBG, NR3C1 | PGR 1/4885CYP3A4 990/4885LMNA 713/4885 |
| US-20160108081-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | CYP21A2, PGR, CYP17A1 | PGR 2/4885CYP3A4 169/4885LMNA 1824/4885 |
| US-20160168190-A1 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | CYP17A1, HSD17B7, FABP7 | PGR 1364/4885CYP3A4 2366/4885LMNA 1541/4885 |
| US-20140275572-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | CYP21A2, PGR, CYP17A1 | PGR 2/4885CYP3A4 169/4885LMNA 1824/4885 |
| US-20160168188-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | CYP21A2, PGR, CYP17A1 | PGR 2/4885CYP3A4 169/4885LMNA 1824/4885 |
| US-20160184322-A1 | USE OF ent-PROGESTERONE TO BETTER OUTCOMES ASSOCIATED WITH TBI AND mTBI | CRH, SERPINA6, SHBG | PGR 4/4885CYP3A4 1789/4885LMNA 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.